John C. Byrd

John C. Byrd, MD is Distinguished Professor and Chair of the Department of Internal Medicine at the University of Cincinnati College of Medicine, and is recognized internationally as the foremost pioneer in the development of ibrutinib (BTK inhibitor) for chronic lymphocytic leukemia. Dr. Byrd, formerly at The Ohio State University's Comprehensive Cancer Center for over two decades, led the pivotal early-phase and registrational clinical development of ibrutinib in CLL beginning in 2009. He was the principal investigator of the landmark RESONATE trial (NEJM 2014), a phase III study of 391 patients with relapsed/refractory CLL demonstrating that ibrutinib produced dramatic improvements in progression-free survival (HR 0.22) and overall survival (HR 0.43) compared with ofatumumab, leading directly to the breakthrough FDA approval of ibrutinib for CLL in February 2014. He subsequently led the RESONATE-2 trial (NEJM 2015) establishing ibrutinib as superior front-line therapy versus chlorambucil in previously untreated older CLL patients. Prof. Byrd's laboratory has produced foundational mechanistic studies on B-cell receptor signaling, BTK pathway biology, NF-κB activation in CLL, and the mechanisms of ibrutinib resistance. His work catalyzed the entire field of kinase inhibitor therapy in B-cell malignancies, transforming CLL from a disease managed with chemotherapy to one effectively treated with targeted oral agents. He has authored over 600 peer-reviewed publications, is among the most cited researchers in hematologic oncology, and has trained a generation of CLL physician-scientists.